VACCINES

Peptinov’s vaccine approach can be applied to many non-infectious diseases (auto-immune diseases, cancer, chronic pain). It has the potential to displace monoclonal antibodies in large populations with limited access to biologics. The effect duration of Peptinov’s vaccines is temporary (3-4 months). Consequently the vaccines must be administered several times per year. Their production cost is very low.

Peptinov has patented three innovative vaccines against the IL-6, IL-1 and IL-23 cytokines, which have successfully been tested in mice and/or in monkeys. These vaccines represent a technological breakthrough. Compared to standard biologics (i.e. monoclonal antibodies), they present several advantages: very low production costs, ease of use and potentially no resistance to treatment. The anti-IL-6 vaccine will enter human clinical trials in 2018 in patients suffering from rheumatoid arthritis.

 

TARGETED DISEASES


Peptinov develops vaccines to protect against the excessive inflammation observed in several chronic inflammatory diseases such as rheumatoid arthritis (anti-IL-1 and anti-IL-6 vaccines), Horton’s disease (anti-IL-6 vaccine) or systemic sclerosis (anti-IL-6 vaccine), and against cancers. New indications such as chronic pain or allergies are in early development.

 

PRINCIPLE


activeimmun

The active immunization process

Overproduction of cytokines such as IL-6 or IL-1 plays a key and deleterious role in inflammatory processes.

Peptinov’s breakthrough treatment against chronic inflammatory diseases (also called auto-immune diseases) uses tailored peptide-based vaccines targeting the cytokines involved in the pathogenesis of auto-immune diseases. These vaccines are ‘therapeutic vaccines’ in the sense that they must be re-injected every three to four months. They are preventive vaccines against disease complications such as joint destruction or metastasis.

Peptinov’s products are designed to induce the production of anti-cytokine antibodies directly by the patient immune system as any typical vaccination. These antibodies neutralize internal pathogenic cytokine overproduction. In doing so, Peptinov’s vaccines have a similar action compared to monoclonal antibodies.

This is accomplished through immunizations against carefully selected, highly immunogenic peptide sequences of these cytokines designed by Peptinov’s team using its bioinformatics computing platform.

 

REFERENCES


Capini et al. Active immunization against murine TNFα peptides in mice: generation of endogenous antibodies cross-reacting with the native cytokine and in vivo protection. Vaccine. 2004;22(23-24):3144-53. PMID: 15297057.

Bertin-Maghit et al. Improvement of collagen-induced arthritis by active immunization against murine IL-1beta peptides designed by molecular modelling. Vaccine. 2005;23(33):4228-35. PMID: 16005738.

Ratsimandresy et al. Active immunization against IL-23p19 improves experimental arthritis. Vaccine. 2011;29(50):9329-36. PMID: 22008816.

Desallais et al. Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis. Arthritis Res Ther. 2014;16(4):R157. PMID: 25059342

Desallais et al. Immunization against an IL-6 peptide induces anti-IL-6 antibodies and modulates the Delayed-Type Hypersensitivity reaction in cynomolgus monkeys. Scientific Reports. 2016 Jan 19;6:19549. PMID: 26782790